title: The investigational new drug application--who benefits?
authors.affiliation: Special Medical Education Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. efreirei@mdanderson.org
authors.forename: Emil J
authors.initials: EJ
authors.lastname: Freireich
mesh_terms: D000046:Academic Medical Centers; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D028744:Ethics Committees, Research / Q000941:ethics; D033161:Government Regulation; D006805:Human Experimentation / Q000941:ethics / Q000331:legislation & jurisprudence*; D006801:Humans; D017387:Investigational New Drug Application / Q000331:legislation & jurisprudence*; D009369:Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents